{
    "startDate": "2020-01-01",
    "endDate": "2020-09-30",
    "year": "2020",
    "quarter": "Q3",
    "symbol": "SNSS",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 26048000
            },
            {
                "label": "Prepaids and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 1576000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 27624000
            },
            {
                "label": "Operating lease right-of-use asset",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 409000
            },
            {
                "label": "ASSETS",
                "concept": "Assets",
                "unit": "usd",
                "value": 28033000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 150000
            },
            {
                "label": "Carrying value as of the balance sheet date of obligations incurred through that date and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                "concept": "snss:AccruedClinicalExpenseCurrent",
                "unit": "usd",
                "value": 380000
            },
            {
                "label": "Accrued compensation",
                "concept": "EmployeeRelatedLiabilitiesCurrent",
                "unit": "usd",
                "value": 901000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "OtherAccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 1727000
            },
            {
                "label": "Operating lease liability - current",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 409000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 3567000
            },
            {
                "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 3567000
            },
            {
                "label": "Commitments and contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Convertible preferred stock",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": 5545000
            },
            {
                "label": "Common stock",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 2000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 718522000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -699603000
            },
            {
                "label": "Stockholders\u2019 equity:",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 24466000
            },
            {
                "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 28033000
            }
        ],
        "cf": [
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -16803000
            },
            {
                "label": "Stock-based compensation expense",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 1106000
            },
            {
                "label": "Accretion of investment discounts and depreciation",
                "concept": "DepreciationAmortizationAndAccretionNet",
                "unit": "usd",
                "value": -41000
            },
            {
                "label": "Amortization of debt discount and debt issuance costs",
                "concept": "AmortizationOfFinancingCostsAndDiscounts",
                "unit": "usd",
                "value": 35000
            },
            {
                "label": "Prepaids and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": -219000
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": -641000
            },
            {
                "label": "The net change during the reporting period in the obligations incurred and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered.",
                "concept": "snss:IncreaseDecreaseInAccruedClinicalExpense",
                "unit": "usd",
                "value": -141000
            },
            {
                "label": "Accrued compensation",
                "concept": "IncreaseDecreaseInEmployeeRelatedLiabilities",
                "unit": "usd",
                "value": -84000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "IncreaseDecreaseInOtherAccruedLiabilities",
                "unit": "usd",
                "value": 574000
            },
            {
                "label": "Cash flows from operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -15776000
            },
            {
                "label": "Purchases of marketable securities",
                "concept": "PaymentsToAcquireMarketableSecurities",
                "unit": "usd",
                "value": 747000
            },
            {
                "label": "Proceeds from maturities of marketable securities",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": 17154000
            },
            {
                "label": "Cash flows from investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": 16407000
            },
            {
                "label": "Principal payments on notes payable",
                "concept": "RepaymentsOfNotesPayable",
                "unit": "usd",
                "value": 5500000
            },
            {
                "label": "Proceeds from issuance of common stock, net",
                "concept": "ProceedsFromIssuanceOfCommonStock",
                "unit": "usd",
                "value": 12633000
            },
            {
                "label": "Proceeds from exercise of stock options and stock purchase rights.",
                "concept": "snss:ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights",
                "unit": "usd",
                "value": 23000
            },
            {
                "label": "Cash flows from financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 7156000
            },
            {
                "label": "Net increase in cash, cash equivalents and restricted cash",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 7787000
            },
            {
                "label": "Conversion of preferred stock to common stock",
                "concept": "ConversionOfStockAmountConverted1",
                "unit": "usd",
                "value": 6224000
            },
            {
                "label": "Legal expenses accrued as cost of equity financing.",
                "concept": "snss:LegalExpensesAccruedAsCostOfEquityFinancing",
                "unit": "usd",
                "value": -35000
            }
        ],
        "ic": [
            {
                "label": "License and other revenue",
                "concept": "RevenueFromContractWithCustomerExcludingAssessedTax",
                "unit": "usd",
                "value": 120000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 10128000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 6607000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 16735000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -16615000
            },
            {
                "label": "Interest expense",
                "concept": "InterestExpense",
                "unit": "usd",
                "value": 302000
            },
            {
                "label": "Other income, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": 114000
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -16803000
            },
            {
                "label": "Unrealized loss on available-for-sale securities",
                "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
                "unit": "usd",
                "value": -1000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -16804000
            },
            {
                "label": "Shares used in computing net loss per common share",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 12748000
            },
            {
                "label": "Basic and diluted loss per common share:",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -1.32
            }
        ]
    }
}